Vertex Announces the Date of its Third Quarter 2011 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2011 financial results on Thursday, October 27, 2011 after the financial markets close. The company will host a conference call at 5:00 p.m. EDT.

The conference call will be webcast live and a link to the webcast may be accessed from the ‘Events & Presentations’ page of Vertex’s website at www.vrtx.com. A replay of the conference call and webcast will be archived on the company’s website until November 10, 2011. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.

About Vertex

Vertex creates new possibilities in medicine. Our team aims to discover, develop and commercialize innovative therapies so people with serious diseases can lead better lives.

Vertex scientists and our collaborators are working on new medicines to cure or significantly advance the treatment of hepatitis C, cystic fibrosis, epilepsy and other life-threatening diseases.

Founded more than 20 years ago in Cambridge, MA, we now have ongoing worldwide research programs and sites in the U.S., U.K. and Canada.

Vertex’s press releases are available at www.vrtx.com.

VRTX-WEB



CONTACT:

Vertex Pharmaceuticals Incorporated
Lora Pike, 617-444-6755
Director, Investor Relations

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.